The LENAMAINT study, sponsored by Technische Universität Dresden, aimed to evaluate lenalidomide's efficacy in preventing relapse in patients with myelodysplastic syndromes (MDS) or acute myelogenous leukemia (AML) characterized by specific cytogenetic abnormalities post-allogeneic hematopoietic stem cell transplantation (HSCT). Despite the promising hypothesis, the trial was terminated due to low recruitment and concerns regarding the scientific rationale and potential adverse effects, such as graft-versus-host disease (GVHD). This raises questions about lenalidomide's positioning in the treatment landscape for high-risk MDS and AML patients, particularly in the context of competitive therapies and the ongoing need for effective post-transplant maintenance strategies. The termination of this study may impact Celgene Corporation's (now part of Bristol-Myers Squibb) strategic focus on lenalidomide, necessitating a reevaluation of its market potential in this indication.